Introduction
============

Human T Cell Leukemia Virus
---------------------------

Human T-cell leukemia virus type I (HTLV-I) retrovirus belongs to the deltaretroviridae family of viruses (reviewed in [@B100]). It is the first described oncogenic retrovirus and is responsible for a spectrum of diseases, the most aggressive of which is Adult T Cell Leukemia (ATL) ([@B127]; [@B55]; [@B165], reviewed in [@B160]; [@B167]). Approximately 5--20 million people are infected with HTLV-I worldwide (reviewed in [@B40]). However, the highest prevalence is reported in endemic areas that include Japan, the Caribbean, South America, inter-tropical Africa, Pacific islands, some areas in the Middle East, and Romania ([@B114], reviewed in [@B24]; [@B40]). The genome of this virus encodes for classical structural proteins required for retroviral replication and a series of accessory and regulatory proteins including the viral transcriptional activator Tax ([@B87], reviewed in [@B2]) and the HTLV-I bZIP factor gene (HBZ), a viral protein encoded from the 3′ long terminal repeat (LTR) in the complementary strand of the proviral genome ([@B39], reviewed in [@B101]; [@B41]; [@B90]). Both Tax and HBZ are linked to HTLV-I pathogenesis (reviewed in [@B16]; [@B71];[@B41]).

Adult T Cell Leukemia
---------------------

Adult T cell leukemia is an aggressive hematological malignancy with very poor prognosis, high relapse rate, resistance to therapy, and a limited survival rate ([@B150]; reviewed in [@B53]; [@B9], [@B10]; [@B43]; [@B96]; [@B107]; [@B160]). ATL develops in around 5% of infected carriers, following a long latency period exceeding 20 years (reviewed in [@B65]; [@B4]).

Adult T cell leukemia is characterized by the presence of leukemic cells with atypical morphology and lobulated nucleus ([@B140]). The majority of these cells are mature CD3^+^ CD4^+^ CD25^+^ CD7^-^ cells exhibiting an increased expression of the alpha chain of interleukin 2 receptor (IL-2R) but also an overexpression of Foxp3, a marker of T regulatory (T~reg~) cells ([@B158]; [@B139]; [@B120]; [@B72]).

Tax as a Viral Oncoprotein
--------------------------

Tax is a 40 kDa viral transactivator protein that promotes viral transcription via the 5′-LTR. Tax functions as an oncogene resulting in leukemia ([@B46]; [@B152]). In rat fibroblasts, the expression of Tax is sufficient for induction of transformation and development of tumors ([@B46], [@B45]; [@B152]). Tax trans-activates transcription by activating promoters implicated in cell proliferation, activation, and survival leading to accumulation of diverse genetic and epigenetic mutations, genetic instability, cell cycle checkpoint disruption, and damage of DNA repair mechanisms (reviewed in [@B97]; [@B78]; [@B6]; [@B160]). Tax binds critical transcription factors including the cAMP response element binding protein ([@B172]; [@B17]; [@B42]), AP-1 ([@B34]; [@B69]), and serum response element (SRF) ([@B35], [@B36]). In addition, Tax inactivates tumor suppressor genes including p53 ([@B126]; [@B128]) and p16 ([@B147]), represses the expression of cyclin A, and antagonizes apoptosis through inhibiting apoptotic genes expression such as Bax and promoting anti-apoptotic ones including Bcl-xL and BFI-1 ([@B18]; [@B111]; [@B97]; [@B91]).

Importantly, Tax activates the NF-κB pathway ([@B146]; [@B44]; [@B105]; [@B57]), after binding the regulatory subunit of the IkappaB kinase (IKK) complex called nemo or IKK-γ ([@B51]; [@B76]; [@B159]) resulting in the activation of downstream effector genes (reviewed in [@B77]). Furthermore, Tax induced NF-κB activation is highly dependent on its post translational modifications namely ubiquitylation and sumoylation (reviewed in [@B78]). Tax also affects the expression of various micro RNAs (mi-RNA) including mi-RNA31 known to inhibit the expression of the NF-κB non-canonical pathway components ([@B161]). Tax-induced mi-RNA31 downregulation occurs via a deregulation of polycomb proteins, leading to a consequent activation of NF-κB, and inhibition of apoptosis in ATL cells ([@B161]). Moreover, Tax modulates the microenvironment and increases ATL cells' invasion and extravasation through affecting gap junctions between endothelial cells and infected cells ([@B28]; [@B9]).

Due to genetic/epigenetic alterations in the HTLV-I genome, including mutations and promoter methylation, most ATL cells lack detectable Tax expression ([@B151]). Despite its undetectable levels in ATL patients ([@B100]), Tax is essential for ATL cells survival as its silencing results in cell death ([@B21]; [@B6]). Recent data revealed transient Tax expression in the form of Tax bursts (Tax expression switching on/off) occurring in a small fraction of ATL-derived or HTLV-I transformed cells ([@B94], reviewed in [@B3]). In a similar context, ATL epigenome was analyzed and an ATL-specific "epigenetic code" paramount for cell identity was deciphered ([@B37]). In more details, Tax was shown to induce an epigenetic-dependent global alteration including increased polycomb complex 2 (PRC2) trimethylation at histone 3 (H3k27me3) resulting in cellular transformation, immortalization, and epigenome reprogramming, similar to that observed in ATL patients ([@B37]). All these properties make Tax an ideal oncoprotein for *in vivo* investigation.

HBZ Biology in ATL
------------------

HBZ is a nuclear protein encoded by the complementary strand of HTLV-I RNA genome ([@B86]; [@B39]). Unlike Tax that is often undetected in ATL cells, *Hbz* gene undergoes no abortive mutations and the protein is expressed in all ATL patients and HTLV-I infected carriers ([@B31]; [@B74]; reviewed in [@B137]; [@B101]). HBZ was found to be a negative regulator of Tax-mediated viral transcription ([@B39]). This opposite expression pattern of the two proteins may indicate a possible differential role in HTLV-I pathogenesis and suggests HBZ as a candidate for a possible HTLV-I vaccine ([@B95]; [@B145]). The mRNA of HBZ positively correlates with the proviral load of HTLV-I in carriers, and ATL patients ([@B134]). *In vitro*, HBZ promotes the proliferation of ATL cells but its suppression by short hairpin RNA (shRNA) results in modest inhibition of ATL cells proliferation ([@B137]; [@B1]). HBZ affects several cellular pathways implicated in cellular proliferation such as NF-κB ([@B174]; [@B122]), AP-1 ([@B99]), JunD ([@B154]; [@B83]), c-Jun, JunB ([@B5]), and CREB ([@B88]). In contrast to Tax which constitutively activates both canonical and non-canonical NF-κB pathways, HBZ was shown to inhibit the canonical pathway of NF-κB via proteasomal degradation of p65 while the non-canonical pathway was not affected ([@B174]; [@B122]).

Animal Models in ATL
--------------------

Due to the complexity of HTLV-I associated diseases and the enigmatic mechanisms dictating their occurrence, in particular in ATL, animal models have been instrumental in providing a platform for answering pivotal questions related to HTLV-I infection, disease progression, and importantly developing new effective therapeutic approaches (reviewed in [@B27]; [@B112]). Among these models, rabbits, monkeys but also rats were useful to understand early HTLV-I viral infection and transmission as well as the induced host immune response against the virus (reviewed in [@B27]). More recently, transgenic *Drosophila* models expressing Tax in the compound eye and plasmatocytes were generated ([@B141]). However, mice remain by far one of the most efficient tools helping in understanding the biology of this affliction. Murine ATL models include transgenic animals for the viral proteins Tax and HBZ, xenografts inoculated with ATL cells (either cells lines or patient-derived cells) and humanized mouse models (reviewed in [@B121]; [@B112]). In this review, we attempt to provide an updated summary of these various mouse models, the key advances they offered in the understanding of HTLV-I infection, as well as their contribution to ATL research and drug development.

Mouse Models of ATL
===================

Immunocompromised Mouse Models
------------------------------

Mice are relevant tools to study the molecular mechanisms of carcinogenesis and to develop new antitumor therapies. However, in immunocompetent mice, transplantation is often hindered by the functional host immune response resulting in low or no tumor engraftment. This problem was overcome after the discovery of the immunocompromised CB17 *scid*/*scid* (SCID) mouse model making a revolution in the cancer field. These mice harbor a spontaneous non-sense mutation in the *scid* gene, encoding for the protein kinase DNA activated catalytic polypeptide (Pkrdc), indispensable for efficient B and T lymphocytes recombination ([@B15]). The loss of *Pkrdc* results in impaired adaptive immunity whereby B and T cells are both non-functional. Despite the lack of adaptive immunity, SCID mice retain a normal innate immunity in which macrophages, antigen-presenting cells, and natural killer (NK) cells carry normal functions ([@B15]).

To further improve tumor engraftment, a non-obese diabetic (NOD/SCID) model exhibiting additional mutations resulting in further impairment of NK activity was generated ([@B142]). This model was further immunosuppressed to generate the NOD/SCID β2-microglobulin^null^ mice in which the *β2-microglobulin* gene was deleted resulting in a complete abolishment of the NK cell activity ([@B80]). Importantly, a NOD/SCID IL2-Rγ^-/-^ or NSG model was generated by deletion or truncation of the gamma chain of IL-2R ([@B67]), reviewed in ([@B68]). Therefore, in addition to all the abnormalities of their predecessors, NSG mice possess a defective production of IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 as well as a severe impairment of the dendritic cell (DC) and their capacity to produce interferon γ (IFN-γ) upon stimulation ([@B67]; [@B63]). For further immunosuppression, the Rag2^-/-^γc^-/-^ model was established. These mice have a deletion of the Recombination Activating Genes (*RAG2*), impairing the production of both T and B cells and NK cell-mediated immunity in murine hosts. Moreover, because the rag proteins are not involved in DNA repair, *RAG2*-deleted mice do no show the leakiness or radio-sensitivity observed in SCID mice ([@B155]; reviewed in [@B20]). Because of these properties, these mice allowed to study human hematopoiesis ([@B56]; [@B63]; reviewed in [@B124]).

ATL Development in Xenograft Mouse Models
-----------------------------------------

The use of xenograft mice has provided invaluable information pertaining to the tumorigenic and proliferative potential of ATL ([@B116]). Under this section, we will provide an overview of most tested immunocompromised animals injected with HTLV-I-transformed or ATL-derived cell lines or those injected with patient-derived ATL cells. Initial xenograft studies investigating ATL development and progression were performed in the SCID mouse model ([@B61]; [@B33]; [@B81]). Later studies reported the use of NOD/SCID and SCID/Beige mice for injection of transformed or immortalized cell lines ([@B89]). More recently, an HBZ xenograft mouse model was generated by transplantation of retrovirally transduced T cells with Bcl-xL, AKT, and HBZ ([@B73]). Only mice groups transplanted with T cells triply transduced with plasmids encoding for the three proteins generated tumors, highlighting the need of key components from different cellular pathways along with the viral HBZ for cellular transformation ([@B73]) (**Table [1](#T1){ref-type="table"}**).

###### 

Summary of the contribution of mouse models to ATL biology.

  Model                                                                                                           Contribution to ATL biology                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Reference
  --------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------
  **Xenografts**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Xenograft mouse models injected with HTLV-I transformed, ATL-derived cell lines or ATL patients derived cells   Represented a platform for targeted drug development. Provided a potential tool to test therapeutic agents:-- Targeting the constitutively active NF-κB pathway. -- Specifically targeting leukemic cells. Allowed a better understanding of the immune response against HTLV-I. Was instrumental for studying early stages of primary HTLV-I infection and subsequent clonal proliferation. Allowed the assessment of early steps of HTLV-I infection, proviral load, and clonal proliferation.   [@B175];[@B64];[@B98];[@B135][@B125];[@B171], [@B169];[@B92], [@B93][@B61];[@B32];[@B143];[@B156];[@B89][@B104][@B149]
  **Humanized**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  HTLV-I infected human CD34^+^ in Rag2^-/-^ gamma c^-/-^ mice models                                             Allowed the understanding of early infection stages. Confirmed the *in vivo* correlation of Tax and NF-κB activation upon expansion of CD4^+^CD25^+^ malignant cells.                                                                                                                                                                                                                                                                                                                              [@B157]
  HTLV-I infected human CD133^+^ in NSG                                                                           Generated a human adaptive immune system in immunodeficient mice. Was the closest model to recapitulate the *in vivo* ATL development.Assessed the initiated immune system against the virus and clonal selection.                                                                                                                                                                                                                                                                                 [@B153]
  ***Tax* Transgenics**LTR-*Tax*-Tg                                                                               Established Tax as an oncoprotein and HTLV-I as transforming virus resulting in mesenchymal tumors and neurofibroma.                                                                                                                                                                                                                                                                                                                                                                               [@B54];[@B109]
                                                                                                                  Showed that Tax expression in oxidative fibers resulted in HTLV-I associated myopathies.                                                                                                                                                                                                                                                                                                                                                                                                           [@B110]
                                                                                                                  Showed that Tax induced autoimmune like Sjogren like syndrome.                                                                                                                                                                                                                                                                                                                                                                                                                                     [@B47]
                                                                                                                  Showed that Tax induced skeletal abnormalities and fragile bones similar to ATL patients.                                                                                                                                                                                                                                                                                                                                                                                                          [@B132]
                                                                                                                  Showed that Tax is arthrogenic and induced ankylotic arthropathy.                                                                                                                                                                                                                                                                                                                                                                                                                                  [@B49]
                                                                                                                  Showed that Immune system activation contributes to ATL pathogenesis in infected carriers.                                                                                                                                                                                                                                                                                                                                                                                                         [@B148]
  Double transgenic -β*gal*-Tg modelLTR-*Tax* HTLV-I LTR                                                          Unveiled tissues supporting tax-mediated transcriptional transactivation. Provided a model system to study the mechanism of gene regulation by Tax.                                                                                                                                                                                                                                                                                                                                                [@B14]
  huGMZB*Tax*GMZ-*Tax*-TgGranzyme promoter                                                                        First model to generate leukemia (LGL), tumor infiltration, and splenomegaly partly resembling ATL.                                                                                                                                                                                                                                                                                                                                                                                                [@B48]
                                                                                                                  Showed that Tax functionally inactivates P53 contributing to late stage tumor progression.                                                                                                                                                                                                                                                                                                                                                                                                         [@B128]
                                                                                                                  Showed that innate immune system, specifically IFN-γ, is crucial for ATL development.                                                                                                                                                                                                                                                                                                                                                                                                              [@B103]
                                                                                                                  Revealed malignant hypercalcemia and osteolytic bone lesions resembling human ATL.                                                                                                                                                                                                                                                                                                                                                                                                                 [@B38]
                                                                                                                  Showed that Tax expression *in vivo* induced constitutive activation of HTLV-I.                                                                                                                                                                                                                                                                                                                                                                                                                    [@B13]
                                                                                                                  Revealed that Tax activation of lymphocytes recruits, activates, and transforms NK/T-cells.                                                                                                                                                                                                                                                                                                                                                                                                        [@B130]
  CD3- *Tax* TgCD3-epsilon promoter/enhancer                                                                      Model failed to develop leukemia. Tax expression closely associated with apoptosis *in vivo*.                                                                                                                                                                                                                                                                                                                                                                                                      [@B50]
  tTA/*Tax* miceBi-transgenic doxycycline inducible model, EmuSR alpha promoter-enhancer                          Revealed ATL-like cutaneous lesions and splenomegaly via HTLV-I activation. Showed that Tax or HTLV-I suppression resolves cutaneous symptoms.                                                                                                                                                                                                                                                                                                                                                     [@B85]
  lck-*Tax*-tg modelLck-proximal promoter                                                                         Showed diffuse large cell lymphoma after prolonged latency. Model exhibits acute ATL like symptoms and HTLV-I activation.                                                                                                                                                                                                                                                                                                                                                                          [@B52]
                                                                                                                  Provided a candidate ATL stem cells of CD38^-^/CD71^-^/CD117^+^ phenotype and decreased expression of Tax, Notch, BMI1 were isolated.                                                                                                                                                                                                                                                                                                                                                              [@B163]
  lck-*Tax*-tg modelLck-Distal promoter                                                                           Showed leukemia of mature CD4^+^ cells resembling mature CD4^+^ ATL cells                                                                                                                                                                                                                                                                                                                                                                                                                          [@B119]
  ***HBZ* transgenic***HBZ*-Tg modelCD4-specific promoter/enhancer/silencer                                       Showed systemic inflammation and later lymphoma in 30% of mice upon aging.                                                                                                                                                                                                                                                                                                                                                                                                                         [@B138]
                                                                                                                  Increased effector/memory CD4^+^ cells and functionally impaired CD4^+^ Foxp3^+^ T~reg~ cells.                                                                                                                                                                                                                                                                                                                                                                                                     [@B162]
                                                                                                                  Showed that HBZ promotes a pro-inflammatory phenotype via labile Foxp3 expression.                                                                                                                                                                                                                                                                                                                                                                                                                 [@B144]
                                                                                                                  Showed that HBZ suppresses Th1 cytokines and impairs cell-mediated immunity.                                                                                                                                                                                                                                                                                                                                                                                                                       [@B84]
                                                                                                                  *HBZ*-Tg mice exhibit ATL stem cells of c-kit^+^/CD4^-^/CD8^-^ phenotype.                                                                                                                                                                                                                                                                                                                                                                                                                          
  **Double Transgenic *Tax/HBZ****HBZ/Tax* modelCD4 promoter/enhancer                                             This model failed to generate ATL-like leukemia. Skin lesions, T-cell lymphoma, and splenomegaly with increased CD4^+^ memory and Foxp3^+^T~reg~ cells.                                                                                                                                                                                                                                                                                                                                            [@B173]

### Xenograft Mouse Models as Platforms for ATL Targeted Drug Development

Given its resistance to therapy and its high relapse rate, ATL remains an aggressive disease with an unfavorable prognosis (reviewed in [@B11]; [@B107]). Despite remarkable progress in ATL therapies with the use of antiviral therapy and allogeneic stem cell transplantation ([@B10], [@B7]), most patients relapse highlighting the necessity of novel therapeutic approaches (**Table [2](#T2){ref-type="table"}**).

###### 

ATL mouse models as platform for ATL targeted therapy.

  Model              Drug                                     Drug target                        ATL therapy                                                                                                           Reference
  ------------------ ---------------------------------------- ---------------------------------- --------------------------------------------------------------------------------------------------------------------- -----------
  Xenograft model    Bay 11-7082                              NF-κB                              Prevented tumor growth and infiltration.                                                                              [@B22]
                     Bortezomib                               NF-κB                              Prevented tumor growth in an ED SCID.                                                                                 [@B136]
                     DHMEQ                                    NF-κB                              Prolonged survival and Prevented tumor growth.                                                                        [@B118]
                     9-aminoacridine and Campath-1H           NF-κB and CD25                     Prolonged survival and induced P53-mediated apoptosis.                                                                [@B70]
                     Compound E, Bortezomib, and Romidepsin   γ-secretase, NF-κB, and HDAC       Assessed interaction between Notch-1 and HTLV-I pathways, combination exhibited synergy supporting clinical trials.   [@B166]
                     AR-42                                    HDAC                               Prolonged survival.                                                                                                   [@B175]
                     Campath-1H and HAT or MEDI 507           CD2 and CD25                       Targeting different CD25 epitopes exhibited synergy.                                                                  [@B170]
                     Flavopiridol and HAT                     cyclin-dependent kinase and CD25   Synergy enhancing antitumor effect and survival.                                                                      [@B19]
                     HAT, MAT, and 7G7B6                      CD25                               Inhibited tumor growth.                                                                                               [@B92]
                     7G7/B6 and daclizumab                    CD25                               Presented osteoponin-integrin interaction as novel therapeutic target for ATL.                                        [@B93]
                     Daclizumab and Depsipeptide              CD25 and HDAC inhibition           Improved survival and attenuated tumor infiltration and viral production.                                             [@B59]
                     A20 ShRNA                                A20, ubiquitin-editingEnzyme       Decreased tumor growth and revealed a novel role for ubiquitin-editing enzymes in ATL development.                    [@B135]
                     ABT-737                                  Bcl-2 and Bcl-xL inhibition        Inhibited tumor growth.                                                                                               [@B64]
                     Adoptive patient-autologous Tax-CTL      ATL cells                          Decreased tumor infiltration and enhanced survival *in vivo.*                                                         [@B98]
  Humanized model    Tinofovir and Azidothymidine             Reverse Transcriptase inhibition   Prophylactic potential by blocking primary infection *in vivo.*                                                       [@B104]
                     TARC-PE38                                CCR-4                              CCR4 is a potential ATL target.                                                                                       [@B58]
  Transgenic model   Arsenic/IFN                              NF-κB, Tax, LIC                    Cured ATL via LIC elimination.                                                                                        [@B25]
                     ST1926                                   NF-κB, Tax, LIC                    Highlights retinoids as promising therapies by enhancing survival and decreasing tumor infiltration.                  [@B26]

DHMEQ, dehydroxymethylepoxyquinomicin; HDAC, histone deacetylase; HAT, humanized anti-Tac; MAT, murin anti-Tac; arsenic, arsenic Trioxide; IFN, interferon-alpha; LIC, leukemia initiating cells.

#### Targeting the NF-κB pathway in ATL therapy

Adult T cell leukemia development entails the deregulation of multiple cellular pathways, including the constitutive activation of the NF-κB pathway (reviewed in [@B77]), making this pathway an attractive therapeutic target against ATL. Accordingly, a wide array of NF-κB inhibitors including specific (Bay 11-7082), and non-specific inhibitors (such as bortezomib and Dehydroxymethylepoxyquinomicin DHMEQ), were tested in ATL xenograft mouse models.

Bay 11-7082, specifically inhibiting the NF-κB DNA binding activity, prevented primary tumor growth and leukemic organ infiltration in NSG mice xenografted with HTLV-I infected cell lines ([@B22]). Bortezomib prevented tumor growth in an ED, ATL-derived T cell line, xenografted SCID model ([@B136]). DHMEQ, known to inhibit the activation of NF-κB by preventing the nuclear translocation of its active subunit p65 ([@B117]), showed a significantly prolonged survival and prevented tumor growth in an ATL NSG xenograft mouse model ([@B118]).

In a similar context, a small molecule, 9-aminoacridine (9AA) selectively induced *in vitro* ATL cell death through inhibition of the NF-κB pathway and induction of p53 responsive genes ([@B70]). The efficacy of 9AA alone or in combination with Campath-1H (a monoclonal antibody directed against CD52) was assessed using a xenograft NOD/SCID model, inoculated with MET-1 cells. MET-1 are activated T cells that express CD2, CD3, CD4, CD25, CD122, and CD52. An enhanced survival of tumor bearing mice was reported upon treatment with both compounds as compared to either compound alone. This involved the induction of p53, PARP cleavage, and apoptosis of splenic cells from leukemia-bearing mice ([@B70]).

Finally, and in order to assess the physical and functional interaction between Notch-1 signaling (increased in some ATL patients) and NF-κB activation, the therapeutic efficacy of the γ-secretase inhibitor compound E along with bortezomib and romidepsin, a histone deacetylase inhibitor (HDACI), was explored in an NSG model injected with MT-1 cells ([@B166]). Each of the three reagents alone or in double combination inhibited tumor growth as monitored by tumor size, the level of tumor markers in the serum, and significantly prolonged the survival of tumor-bearing animals ([@B166]).

At the cellular and molecular levels, and to assess the *in vivo* implication of NF-κB in ATL pathogenesis, [@B113] investigated ATL development in a defective NF-κB setting. In this study, alymphoplasia *(aly/aly)* mice bearing an NF-κB inducing kinase (NIK) mutation were used. These mice harbored defects in lymphoid organs development and severe deficiencies in both humoral and cell-mediated immunity. In contrary to BALB/c and C57BL/6J control mice, *aly/aly* animals inoculated with HTLV-I producing MT-2 cells, did not maintain the provirus and antibodies against HTLV-I were not detected suggesting that NIK is required for the initial proliferation and maintenance of HTLV-I infected cells in mice ([@B113]).

#### Targeted ATL drug development other than NF-κB inhibition

One of the suggested approaches in ATL treatment is virotherapy. Oncolytic virotherapy is a relatively new approach in cancer treatment, utilizing replication-competent viruses that selectively target cancer cells while sparing the normal healthy ones ([@B133]). MET-1 NOD/SCID model was used to evaluate the potential of measles-virus-virotherapy in treating ATL. Measles virus treatment of tumor cells lacking type I interferon (IFN-α) secretion was shown to be more efficient both *in vitro* and *in vivo* as compared to other tumor cells ([@B123]). Using the same animal model, [@B175] investigated the therapeutic effect of AR-42, an HDACI, in alleviating HTLV-I-associated lymphoid malignancies. A dietary formulation of AR-42 was shown to prolong survival of ATL engrafted mice as compared to controls.

Non-obese diabetic/SCID xenograft mice were also used to test ABT-737, a small molecule inhibitor of Bcl-2 and Bcl-xL, whereby ABT-737 resulted in a significant inhibition of the tumor growth *in vivo* ([@B64]).

In another study, [@B59] investigated the efficacy of 17-DMAG, an HSP90 inhibitor, as a therapeutic agent against ATL. Oral administration of 17-DMAG dramatically attenuated the aggressive infiltration of multiple organs in an ATL xenograft mouse model. It also inhibited the *de novo* viral production and improved the overall survival of ATL mice ([@B59]).

More recently, an unrecognized role of ubiquitin-editing enzyme, A20, in the survival of HTLV-I-infected cells was unveiled in a SCID model. In brief, the ATL-derived HuT-102 cell line was first transduced with A20 shRNA and then inoculated into SCID mice ([@B135]). Depletion of A20 induced apoptosis and affected the *in vivo* growth of HTLV-I infected cells, highlighting the importance of ubiquitin in ATL development.

#### Monoclonal antibodies as an ATL therapy in xenograft mouse models

The expression of specific cell surface markers on ATL cells implanted into mice, renders them an excellent model for testing the pre-clinical therapeutic potential of monoclonal antibodies. In this context, and given that ATL cells express CD2 and CD25 among other surface markers, the effect of monoclonal antibodies targeted against these two surface markers was performed in NOD/SCID mice intraperitoneally injected with MET-1 cells ([@B171]). Furthermore, the effect of campath-1H (anti CD52), either alone or in combination with a humanized anti-Tac (HAT) or MEDI 507, a monoclonal antibody directed against CD2, was investigated. Campath-1H led to a striking prolongation of the survival of MET-1 ATL-bearing mice. This survival was significantly longer than that of the group receiving HAT. Moreover, the study revealed the anti-leukemic mechanism of action of Campath-1H which involves FcR-gamma-containing receptors (e.g., FcRgamma-III) present on polymorphonuclear leukocytes and macrophages, known to normally mediate antibody-dependent cellular cytotoxicity (ADCC) and/or trigger cross-linking induced apoptosis ([@B171]). The same group explored the use of flavopiridol, a cyclin-dependent kinase inhibitor, alone or in combination with HAT. HAT/flavopiridol combination resulted in a prolonged survival and dramatic enhancement of the antitumor effect in MET-1 NOD/SCID mice as compared to the control group ([@B169]).

A MET-1 NOD/SCID mouse model was also used to investigate the anti-leukemic effects of specific antibodies targeting IL-2R ([@B125]) whereby HAT, murine anti-Tac (MAT), and 7G7/B6, all of which targeting IL-2Rα, significantly delayed leukemia progression resulting in enhanced survival ([@B125]). To decipher the mechanism of action of these antibodies, comparison between treated-NOD/SCID and NSG mice was carried out ([@B168]). In contrast to what was seen in NOD/SCID mice, treatment of NSG mice did not affect leukemia growth nor improved mice survival highlighting that the immune system difference, specifically polymorphonuclear cells, plays a crucial role in leukemia elimination by anti-IL-2R antibodies ([@B168]).

Another promising therapeutic target is CC chemoreceptor 4 (CCR4). CCR4 is a chemokine receptor expressed by tumor cells in about 90% of ATL patients ([@B60]). Several studies have investigated the effect of monoclonal Anti-CCR4 antibodies *in vivo* as potential therapies in ATL ([@B164]; [@B66]; [@B62]; [@B58]). Using an ATL SCID xenograft mouse model, Yano et al. tried to augment the ADCC effect induced by defucosylated chimeric Anti-CCR4 IgG1 monoclonal antibody KM2760 *via* addition of granulocyte colony stimulating factor (G-CSF). Addition of G-CSF resulted in a more robust antitumor effect as compared to KM2670 alone ([@B164]). Using the same model, another monoclonal anti-CCR4 antibody KW-0761 was investigated ([@B62]). KW-0761 also presented promising antitumor activity where tumor volume was significantly decreased ([@B62]).

Anti-CD25 antibodies such as 7G7/B6 and daclizumab, directed against different epitopes of CD25 were also tested either alone or in combination ([@B170]). Overall, 91% of the mice receiving the combination survived showing the promising synergistic effect of these two antibodies, especially when compared to the single antibody treatment ([@B170]). In a similar study and using the same model, daclizumab was investigated in combination with an HDAI, depsipeptide, and showed an enhanced antitumor effect and survival of the leukemia-bearing mice, compared with those in the depsipeptide or daclizumab alone groups ([@B19]).

Given that some ATL cells express CD30 on their surface, the therapeutic effect of two anti-CD30 monoclonal antibodies was also investigated. SGN-30, a chimeric anti-CD30 mAb, and SGN-35, a monomethyl auristatin E-conjugated anti-CD30 mAb, were used. [@B92] treated NOD/SCID mice subcutaneously engrafted with HTLV-I-infected cells and reported a significant inhibition of the tumor growth upon treatment with either antibodies ([@B92]).

In another context, the therapeutic efficacy of adoptive patient-autologous Tax-specific cytotoxic T cells (Tax-CTL) was assessed in NSG mice bearing primary ATL cells from three patients. Tax-CTL treatment resulted in a significant decrease of ATL cell infiltration into blood, spleen, and liver as well as a significant prolonged survival time in ATL NSG mice that received cells from two out of three patients ([@B98]).

More recently, the NSG mice were used to investigate the physiological roles of osteopontin (OPN)-integrin interaction in ATL pathogenesis *in vivo*. ATL cell lines inoculated into NSG mice resulted in an increased OPN plasma levels. Treatment of these mice with anti-OPN mAbs inhibited not only tumor growth but also tumor invasion and metastasis suggesting a pivotal role of OPN in these processes ([@B93]).

Altogether, the above studies highlight the importance of xenograft mice models in targeting and understanding ATL.

Humanized Mouse Models of ATL
-----------------------------

Despite the importance of ATL xenograft mouse models, these models present with the limitation of being injected with ATL-derived or HTLV-I-transformed cell lines that were maintained for years in culture. This entails the potential changes in their genetic drift and the attenuation in their *in vivo* potential. Moreover, ATL xenograft mouse models do not provide answers to how HTLV-I induces ATL at early steps and how it maintains leukemogenesis (reviewed in [@B112]). In this context, humanized mouse models were generated (reviewed in [@B121]; [@B23]; [@B112]) (**Table [1](#T1){ref-type="table"}**).

### Humanized Mouse Models: A Transformation in ATL Biology and Immune Responses

The lack of an adaptive and/or innate immune system is advantageous for HTLV-I replication and tumor engraftment. Injecting CD34^+^ hematopoietic stem cells into NSG mice resulted in generation of human lymphocytes. The first humanized ATL model was developed by [@B104] in which human peripheral blood mononuclear cell (PBMC) were first injected in NSG mice to establish a human-like setting followed by inoculation of HTLV-I virus producing MT-2 cells. MT-2 cells ensured cell-to-cell transmission required for HTLV-I infection. In this model, proviral load was increased in both CD4^+^ and CD8^+^ cells ([@B104]).

In a similar study, PBMC from HTLV-I infected carriers were injected in NSG mice to establish HTLV-I infection ([@B149]). Despite the different methodology, both studies resulted in mice harboring human infected cells, which later undergo clonal proliferation ([@B104]; [@B149]).

Another humanized model was developed by [@B157] whereby CD34^+^ human umbilical stem cells (HUSC) were intra-hepatically inoculated into newborn BALB/c/Rag22/2IL-2Rgc2/2 (also known as *BRG* mice) mice generating human lymphocytes. These lymphocytes were later infected by intraperitoneal injection of irradiated HTLV-producing MT-2 cell line. This study reported an alteration in T cell development alongside an increase in the proviral load and expansion of CD4^+^CD25^+^ cells. Mice also developed ATL- like splenomegaly as well as lymphoma ([@B157]).

In a different study, intra-bone marrow injection (IBMI) of cord blood CD133^+^ stem cells intratibialy into sublethally irradiated NSG mice was performed ([@B153]). This study is based on the idea that CD133^+^ cells are believed to be the ancestral of CD34^+^ in hematopoiesis and carry the potential to differentiate to any hematopoietic cells including lymphocytes ([@B153]; reviewed in [@B23]). One month following CD133^+^ inoculation, human CD45^+^ leukocytes were found to completely reconstitute the murine bone marrow. Later, human B and T lymphocytes were detected and a balanced B/T lymphocyte ratio was attained and remained stable for up to 8 months ([@B153]). After establishing a human immune system in this model, HTLV-I infection involved the injection of sublethally irradiated MT-2 cells known to produce HTLV-I. Shortly after infection, an increase in CD4^+^ cells was reported where CD4^+^ CD25^+^ clones gradually dominated indicating clonal selection. ATL like features including splenomegaly, hepatomegaly with ATL infiltration, and ATL-like "flower cells" were also reported ([@B153]). Screening of cytokines profiles demonstrated an initial elevation in the levels of IL-6, IL-8, IL-10, IL-12, IL- 13, IFN-γ, and TNF-α. In addition, granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemokine (C-C motif) ligand 4 were also increased, clearly referring to an initiated immune response against the virus ([@B153]). One of the main findings of this study was the generation of a functional adaptive immune response in a humanized mouse model, summarized by detection of anti-HTLV-I antibodies as well as Tax-specific cytotoxic T cells (CTL). These CTL inversely correlated with proviral load of infected cells ([@B153]). Thus Tezuka's model was by far the closest one in recapitulating the development of ATL *in vivo*. While most of the other humanized models developed lymphoma and/or thymoma, Tezuka's model exclusively developed leukemia. This may be due to the fact that infection was carried out after a humanized immune system may be fully developed.

Another humanized ATL model was generated by [@B106] where PBMC from ATL patients were injected into NOD/SCID/Jak3-null mice (NOJ mice). In Brief, the model involved subcutaneous injection of the ATL S1T cell line into mice, followed by subcutaneous, intraperitoneal, or intravenous transplantation of primary ATL cells. ATL cells successfully infiltrated various organs and could transplant into secondary mice establishing NOJ mice as successful models for primary ATL xenotransplantation ([@B106]).

### Humanized Models as Platforms for ATL Therapy

After the revolution that humanized mouse models generated in the ATL field, they provided a strong platform for testing anti-ATL therapies (**Table [2](#T2){ref-type="table"}**). Two antiviral reverse transcriptase inhibitors, Tenofovir and Azidothymidine, were tested in the first humanized ATL model developed by [@B104]. After the uncertain role of these agents in halting HTLV-I infection, their prophylactic potential was investigated. Both agents were reported to block primary infection in these mice ([@B104]).

Moreover, humanized models proved instrumental in investigating the anti-tumor potential of anti-CCR4 antibodies. NSG mice inoculated with primary ATL cells and autologous immune cells belonging to the same patient were used to assess the antitumor efficacy of KM2760 antibody ([@B66]). KM2760 decreased the number of ATL cells in blood, spleen, and liver, as well as ATL lesions and organ infiltration, and lowered IL-2R concentration in serum ([@B66]). Using a humanized mouse model similar to that developed by [@B157], the efficacy of TARC-PE38 targeting CCR4 was investigated ([@B58]). TARC-PE38 is a complex of thymus and activation-regulated chemokine (TARC), CCR4 ligand, fused to a truncated *Pseudomonas aeruginosa* exotoxin A (PE38). TARC-PE38 efficiently killed HTLV-I-infected cell lines and shrank HTLV-I-associated solid tumors size. Moreover, TARC-PE38 markedly inhibited the proliferation of HTLV-I-infected human CD4^+^CD25^+^ or CD4^+^CD25^+^CCR4^+^ cells and reduced the proviral loads in PBMC obtained from both patients and asymptomatic carriers ([@B58]).

Using the NOJ model generated by [@B106] the antitumor effect of pyrrolidine dithiocarbamate (PDTC), an antioxidant agent, was tested in ATL and showed that PDTC significantly enhanced the survival of these mice ([@B106]).

Transgenic Mouse Models of HTLV-I
---------------------------------

To decipher the oncogenic potential role of HTLV-I proteins *in vivo*, transgenic mice overexpressing the viral oncoproteins Tax or HBZ were generated. So far several *Tax* transgenic models expressing Tax under different promoters and two *HBZ* models were developed. Despite exhibiting many features of ATL, none of these models could exactly recapitulate HTLV-I-associated ATL. For instance, and as opposed to HTLV-I infection where HBZ- and Tax-specific CTLs and antibodies are generated, transgenics for both oncoproteins lack a host induced immune response against these viral proteins. the importance of transgenic models in the ATL context lies in confirming the oncogenic functions of HTLV-I proteins, Tax and HBZ, *in vivo* and in disclosing various host pathways manipulated by these proteins ultimately leading to tumor generation (**Table [1](#T1){ref-type="table"}**).

### Tax Transgenic Models Develop ATL-Like Leukemia/Lymphoma

#### Tax transgenic mice

The generation of *Tax* transgenic models relied on the earliest discoveries of the *in vitro* Tax oncogenic potential, from independent laboratories ([@B46]; [@B152]). To investigate the *in vivo* role of Tax in leukemogenesis, several mouse models have been generated (reviewed in [@B115]; [@B112]). Depending on the used promoter, Tax expression resulted in various tumors ([@B115]). Except for models utilizing the lymphocyte-specific protein tyrosine kinase p56 (lck) or granzyme promoters, most of the models could not generate leukemia/lymphoma and rather resulted in less typical HTLV-I tumors and manifestations ([@B115]; [@B121]; [@B112]). [@B109] established the first *Tax* transgenic mouse where *Tax* gene was under the control of the natural HTLV-I promoter, the LTR promoter \[Tg (HIV-*tat*) 6-2Gja\] ([@B109]). Referred to initially as tat protein, Tax exhibited tissue-specific expression and LTR-*Tax* mice mainly developed mesenchymal tumors in the nose, ear, mouth, tail, as well as the foot. Despite not recapitulating human ATL, this research was novel in establishing Tax as an oncoprotein and HTLV-I as a transforming virus *in vivo* ([@B109]). Beside mesenchymal tumors, LTR-*Tax* mice developed tumors at other multiple sites resembling neurofibroma making this model useful for studying neurofibromatosis ([@B54]). Apart from tumors, mice were shown to develop myopathies similar to those associated with HTLV-I, which are due to the atrophy/degeneration of oxidative muscle fibers ([@B110]). Using the same model, [@B49] reported high incidence of inflammatory polyarthropathy resembling arthritis. Profound skeletal alterations resulting in fragile bones with high turnover rate were also reported ([@B132]). Salivary and lacrimal glands showed exocrinopathy and lesions resembling Sjogren's syndrome due to the attack by immune cells ([@B47]).

Afterwards, a bi-transgenic mouse was generated by crossing LTR-*Tax* mice with LTR-β *gal* mice (β-galactosidase) to better visualize the organ involvement in ATL ([@B14]). Tax acts on the LTR resulting in an increased β-gal expression; and this enzyme was detected in specific tissues including bones, muscles, exocrine glands, as well as mesenchymal tumors ([@B12]; [@B14]). Using this same model, [@B148] assessed the interaction with the host immune system and demonstrated that the activation of infected CD4^+^ T cells may induce Tax expression and thus may contribute to ATL pathogenesis in infected carriers. In addition, infected CD4^+^ cells harboring Tax exhibited changes in the expression of surface markers and resulted in changes in CD4^+^ subtype specifications ([@B148], reviewed in [@B82]). Despite not developing leukemia/lymphoma, the LTR-*Tax* model provided a clear-cut evidence that Tax expression is solely sufficient for tumor induction establishing Tax as an oncoprotein *in vivo*.

In another attempt, a *Tax* transgenic model of C57BL/6TgN mice (huGMZB*Tax*) was developed where *Tax* expression was controlled by the granzyme B promoter ([@B48]). This promoter restricted the expression of Tax to the T cell compartment specifically CD4^+^ and CD8^+^, NK, and lymphokine activated killer cells. In this model, mice developed large granular lymphocytic leukemia (LGL), neutrophil dominated inflammation, as well as tumors on the ears, tail, and leg ([@B48]). Mice also developed symptoms resembling human ATL such as high white blood cell count, splenomegaly, neutrophilia, and lymphadenopathy. LGL cells disseminated to distant organs such as lungs, bone marrow, and liver ([@B48]). Despite not fully recapitulating the human disease, this model was instrumental in showing that Tax expression in the lymphocytes is sufficient to cause leukemia. Later, [@B38] demonstrated that these mice also exhibited malignant hypercalcemia and symptoms associated with metastasis such as osteolytic bone lesions which again resemble the disease in ATL patients ([@B38]). Activated NK and T cells from this model demonstrated Tax-mediated constitutive activation of NF-κB in both its canonical and non-canonical pathways ([@B13]). Using the same model, the role of p53 inactivation in Tax-induced tumor development was assessed and showed that the p53 apoptotic pathway was functionally inactivated ([@B128]). P53 mutations in tumors were also detected but were associated with secondary organ infiltration. In the same context, mating of these *Tax*-transgenic mice with P53-deficient mice did not accelerate the initial tumor development ([@B128]). However, it significantly increased disease progression and mortality in *p53* heterozygous mice. This suggested that Tax functionally inactivates p53 which contributes to late stage tumor progression rather than initial tumor formation ([@B128]).

In a different study, the role of the innate immune system and inflammation in ATL development was assessed. The *Tax*-granzyme model was mated with an *IFN-*γ knock-out model. The resulting mice exhibited enhanced tumorigenesis with accelerated lesions development ([@B103]). Using the same model, Rauch et al. generated *Tax*-LUC double transgenic mouse model whereby luciferase bioluminescent imaging techniques allowed to track tumor engraftment *in vivo* ([@B129],[@B130]). The onset of peripheral subcutaneous tumors was preceded by the formation of microscopic intra-epithelial lesions. This suggests that Tax activates lymphocytes, which then recruit NK/T-cells to be activated and transformed ([@B130]). Another study from the same group suggested that in *Tax*-LUC model, lymphoma development is promoted by an inflammatory stimulus whereby T cell activation via T cell receptor (TCR) was shown to promote/exacerbate tumorigenesis ([@B129]). Afterwards, the same *Tax*-LUC model was utilized to investigate the role of IL-15 in spontaneous lymphoma development ([@B131]). IL15^-/-^ *Tax*-LUC mice were generated and resulted in an aggressive lymphoma development and accelerated mortality, suggesting that IL-15 contributes to the antitumor immunity in ATL. Knocking out IL-15 also resulted in elevation of IL-1α and IL-1α driven cytokines ([@B131]). Treatment with anti-IL-1α antibodies resulted in decreased tumor growth. This study suggested IL-15 and IL-1α as potential therapeutic options in ATL.

[@B50] established another *Tax* transgenic model where *Tax* gene was under the control of *CD3-epsilon* promoter-enhancer sequences. These mice, of C57/CBA origins, developed a variety of tumors including salivary and mammary adenomas as well as mesenchymal tumors, specifically at wound sites, yet failed to develop leukemia ([@B50]).

In an attempt to target Tax expression to the leukocyte compartment, a bi-transgenic doxycycline inducible model \[Tg (*EmuSR-tTa*) 83Bop\] was generated ([@B85]). This conditional "tet off" *Tax* transgenic model targeted both wild-type Tax and Tax mutants that selectively compromise NF-κB or CREB pathways to the leukocyte compartment. Wild type *Tax* transgenic mice developed a lethal cutaneous disease with skin lesions infiltrated by CD3^+^CD4^+^MHC-2^+^ T cells, similar to those seen in ATL patients. Mice also developed systemic lymphadenopathy and splenomegaly. Moreover, inflammatory cytokines including TNF-α, IL-6, IL1 α/β, IFN-γ were induced ([@B85]). Of note, suppression of Tax by doxycycline administration resulted in disappearance of skin lesions directly linking Tax to this dermal pathogenesis ([@B85]).

To further restrict Tax expression to the thymus compartment, being the site of maturation of T cells, the two *Lck* promoters, distal and proximal, were used. The proximal promoter drives gene expression in thymocytes while the distal one restricts gene expression specifically to mature T lymphocytes ([@B52]; [@B119]; reviewed in [@B115]). [@B52] generated a *Tax* transgenic model using the *lck* proximal promoter \[C57BL/6-Tg (Lck-HTLV-I *Tax*)\]. As compared to previous transgenic models, Hasegawa's model was the closest to recapitulate ATL. In this model, mice developed CD4^-^CD8^-^CD44^+^CD25^+^ diffuse large cell lymphoma and leukemia after a prolonged latency period of around 18 months resembling the latency period required in humans to generate tumors ([@B52]). Interestingly, mice exhibited clinical and histological resemblance to acute ATL seen in patients, such as characteristic "flower cells" in blood smears, lymphadenopathy, splenomegaly with extensive infiltration by lymphomatous cells, as well as distant organ infiltration of bone marrow, liver, kidney, lung, skin, and meninges. Infiltrating T cells were of malignant phenotype with increased expression of CD25^+^ cell surface marker ([@B52]). In addition, mice exhibited further common features with ATL patients such as significant leukocytosis, hypercalcemia, elevated LDH, and constitutive NF-κB activation ([@B52]). A major difference between Hasegawa's mice and human ATL is in the phenotype of leukemic cells; mice exhibited immature CD4^+^ cells while human ATL involves leukemia generally of mature CD4^+^ cells (reviewed in [@B115]). Since the development of leukemia required a long time, splenocytes derived from this *Tax* transgenic model were intraperitoneally injected in SCID mice. This model recapitulated most of the ATL phenotypes, similar to the transgenic model and to ATL patients, in less than 1 month ([@B52]; [@B25]). Moreover, this model was the first to be used for the isolation of candidate ATL stem cells of CD38^-^/CD71^-^/CD117^+^ phenotype ([@B52]; [@B163]). These stem cells exhibited decreased levels of Notch, Tax, and BMI-1 expression all of which indicate their early hematopoietic cell origin ([@B163]).

The distal promoter of *Lck* was also used to develop *Tax* transgenic mice ([@B119]). The expression of Tax under the distal promoter resulted in leukemia of mature CD4^+^ cells unlike the immature ones obtained in the Hasegawa et al generated *Tax* transgenic model ([@B119]).

#### Tax transgenic models for ATL-targeted therapy

Despite the improvements in prolonging survival of the leukemic subtypes of ATL upon using zidovudine and IFN-α (IFN) ([@B10]), most patients relapse underlying the urgent need for novel therapies and targets. Different drugs and drug combinations were investigated, of which a very promising treatment is the combination of arsenic trioxide (arsenic) and IFN-α (**Table [2](#T2){ref-type="table"}**). *In vitro* studies involving ATL cell lines and primary patients' leukemic cells showed the efficacy of the arsenic/IFN combination in triggering Tax degradation by the proteasome resulting in cell cycle arrest and apoptosis ([@B8]; [@B29]; [@B108]). To assess the efficacy of this combination *in vivo*, El Hajj et al. used spleen cells derived from the murine *Tax* transgenic ATL model ([@B52]) and injected them into SCID mice ([@B25]). Approximately 1 month after transplantation, mice recapitulated ATL manifestations ([@B52]; [@B25]). Strikingly, arsenic/IFN cured ATL in these mice. Although this combination did not rapidly decrease the tumor bulk, as ATL cells only underwent modest cell cycle arrest and apoptosis, the curative efficacy of arsenic/IFN occurred through clearance of leukemia initiating cells (LIC). Briefly, using the serial transplantation method, ATL cells derived from primary mice treated with the arsenic/IFN combination resulted in lower leukemia transplantation ability in untreated secondary mice and no transplantation in untreated tertiary mice ([@B25]). Addition of the proteasome inhibitor bortezomib to arsenic/IFN treatment of primary mice reversed all the observed phenotypes and led to normal ATL development in serial transplantation experiments, demonstrating that Tax degradation is the critical step for LIC exhaustion which further highlighted the oncogenic addiction of ATL cells to Tax ([@B25]). Later, [@B75] have investigated the effect of the triple combination of zidovudine, arsenic, and IFN, and translated the promising pre-clinical results to patients. Interestingly, the triple drug combination of zidovudine/arsenic/IFN resulted in 70% complete remission rate and 100% overall response rate in chronic ATL patients, as well as an unpreceded prolonged survival in some patients, strongly suggesting a similar mechanism of LIC eradication in patients ([@B75]).

Using the same *in vivo* model, the preclinical efficacy of a synthetic retinoid ST1926 was investigated ([@B26]) (**Table [2](#T2){ref-type="table"}**). Oral treatment of ST1926 induced massive apoptosis, prolonged survival and decreased tumor infiltration, leukocytosis, and splenomegaly as compared to untreated group of animals. This study highlights the potential of synthetic retinoids as a promising therapy for ATL ([@B26]). It remains to be determined whether ST1926 treatment alone targets LIC in ATL.

### HBZ Transgenic Models Generate T-Cell Lymphoma but Not Leukemia

#### HBZ transgenic models

The first *in vivo HBZ* transgenic mouse model (*HBZ*-Tg mice) was generated by [@B137], where the *HBZ* gene was expressed under the control of a murine *CD4*-specific promoter/enhancer/silencer ([@B137]). Restricted HBZ expression to CD4^+^ T cells resulted in systemic inflammation and development of T cell lymphoma in only 30% of mice after a long latency period. *HBZ*-Tg spontaneously developed systemic dermatitis, alveolitis, and later lymphoma upon aging ([@B138]). At the cellular level, HBZ increased the generation and proliferation of Foxp3^+^ T cells as well as the transcription of Foxp3 mRNA. *HBZ*-Tg mice exhibited an increase in the number of functionally impaired CD4^+^ Foxp3^+^ T~reg~ cells as well as effector/memory CD4^+^ T cells ([@B138]). Recently, this model was used to investigate whether the proliferation of CD4^+^ T cells is increased *in vivo*. Allergic encephalomyelitis was experimentally induced by immunization with myelin oligodendrocyte glycoprotein (MOG)/complete Freund's adjuvant. Disease severity was not increased but the number of CD4^+^ T cells was increased only in the immunized *HBZ*-Tg mice suggesting that HBZ-expressing T cells have higher susceptibility to immune stimulation *in vivo* ([@B79]). Using the same model, [@B162] showed that HBZ promotes inflammation through labile Foxp3 expression; T~reg~ cells induced by HBZ have unstable Foxp3 expression and tend to convert to Foxp3^-^T cells producing IFN-γ. This HBZ-induced pro-inflammatory phenotype of CD4^+^ T cells was suggested to be involved in the HTLV-I-associated pathogenesis and inflammation ([@B162]). Later, [@B102] closely investigated HBZ-induced inflammation and revealed that in *HBZ*-Tg mice, inflammation severity significantly correlate with lymphoma development. The study suggested a link between HBZ inflammation and oncogenesis in CD4^+^ T cells ([@B102]).

In another context, HBZ expression was found to impair the cell-mediated immunity of HBZ-Tg via suppression of Th-1 cytokine production ([@B144]). Despite being of low immunogenicity, anti-HBZ antibodies can be detected in patient's serum. [@B144] have utilized the *HBZ*-Tg mouse model to investigate the possibility of generation of HBZ-targeted HTLV-I vaccine. Accordingly, splenocytes from HBZ mice, called HT-48, were inoculated into immunodeficient mice generating an ATL model. C57BL/6 mice immunized by a recombinant vaccinia virus-based HBZ vaccine generated HBZ-specific CD4 and CD8 T-cell response. Afterwards, inoculation of anti-HBZ cytotoxic T cells into the generated HT-48 mouse model increased survival of these mice suggesting that HBZ might be a candidate for vaccine production ([@B144]). Recently, ATL stem cells were identified in an HBZ model ([@B84]). In this study, HT-48 cells from *HBZ*-Tg mice were injected intraperitoneally into C57BL/6 mice, then serial transplantation experiments were done to assess the presence of LIC where nine consecutive transplantations were done ([@B84]). Surprisingly, HT-48 cells were able to regenerate leukemia in all transplantations. In this model, ATL stem cells were identified as c-kit^+^/CD4^-^/CD8^-^ cells. Compared to the T cell progenitors, reported ATL stem cells had a similar gene expression profile ([@B84]).

More recently, a transgenic *HBZ* mouse model using Granzyme B (Gzmb-*HBZ*) was generated ([@B30]). In addition to splenomegaly, abnormal white cell count, tumors developing after 18 months, in two thirds of the Gzmb-*HBZ* mice, as well as pathologic bone loss and hypercalcaemia were obtained ([@B79]) (**Table [1](#T1){ref-type="table"}**).

### The Double Transgenic HBZ/Tax Mouse Model Fails to Recapitulate ATL

[@B173] established a double transgenic mouse model expressing both Tax and HBZ viral proteins. In this model, both proteins were exclusively expressed in CD4^+^T cells. The concomitant transgenic expression of both Tax and HBZ resulted in skin lesions, T-cell lymphoma, and splenomegaly resembling in part diseases observed in HTLV-I infected individuals ([@B173]). In addition, HBZ/Tax double expression resulted in an increase in the number of CD4^+^ memory T cells and Foxp3^+^ T~reg~ cells. Overall, they reported that little difference is seen between the phenotype produced by *HBZ*-Tg model and *HBZ/Tax* double transgenic model. However, in contrast to all published findings, this study reported that "Tax expression alone failed to generate major health problems" and did not result in tumor development ([@B173]). In addition, this model resulted in lymphoma and thus failed to generate ATL-like leukemia (**Table [1](#T1){ref-type="table"}**).

Conclusion
==========

In an attempt to unveil the molecular mechanisms dictating ATL development and to advance novel therapeutic options, multiple animal models were utilized. The use of animal models to study HTLV-I infection and ATL development has been instrumental in providing valuable data concerning disease progression and potential therapy targets. Besides ATL patients, mice remain the most valuable and useful tools for *in vivo* investigation of ATL. Generation of ATL xenograft models strikingly advanced the search for targeted therapies for ATL. To assess ATL pathogenesis in a more human setting, humanized models were remarkably helpful. These models are critical for studying early steps of HTLV-I infection. Transgenic ATL models expressing HTLV-I proteins, Tax, HBZ, or both have disclosed the potential roles and contributions of either protein to ATL pathogenesis. In this context, *Tax* transgenic mice, specifically *Lck*-promoter-models, were shown to develop ATL-like leukemia with pathology and molecular changes resembling acute ATL including activation of NF-κB pathway. *Tax* transgenic mice also served as means of testing targeted drug therapies. On the other hand, *HBZ* transgenic mice showed manifestations of systemic inflammation establishing HBZ as a pro-inflammatory protein. Finally, despite the noted progress in disease understanding and its treatment strategies, an animal model that can fully recapitulate the human ATL disease has not been achieved yet.
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